Ibutilide for cardioversion of atrial flutter: Efficacy of a single close in recent-onset arrhythmias

Minerva Cardioangiologica

Volumn 52, Issue 1, 2004, Pages 37-42

  Ando G ^a,b   Di Rosa, S ^a   Rizzo, F ^a   Carerj, S ^a   Bramanti, O ^a   Giannetto, M ^a   Arrigo, F ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b NONE   (Italy)

Author keywords

Anti arrhythmia agents, chemistry; Anti arrhytmia agents, administration and dosage; Atrial flutter, therapy

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; IBUTILIDE;

ADULT; AGED; ARTICLE; CARDIOVERSION; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FLUTTER; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PROPHYLAXIS; QT PROLONGATION; SIDE EFFECT; SINGLE DRUG DOSE; SINUS RHYTHM; TORSADE DES POINTES; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FLUTTER; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; SULFONAMIDES; TIME FACTORS;

EID: 1642289058     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Podrid PJ. Redefining the role of antiarrhythmic drugs. N Engl J Med 1999;340:1910-2.
2. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996;94:1613-21.
3. Ellenbogen KA, Stambler BS, Wood MA, Sager PT, Wesley RC jr, Meissner MC et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996;28:130-6.
4. Lanzarotti CJ, Olshansky B. Thromboembolism in chronic atrial flutter: is the risk underestimated? J Am Coll Cardiol 1997;30:1506-11.
5. Waldo AL. Treatment of atrial flutter. Heart 2000;84: 227-32.
6. Glatter K, Yang Y, Chatterjee K, Modin G, Cheng J, Kayser S et al. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. Circulation 2001;103:253-7.
7. Cheng J, Glatter K, Yang Y, Zhang S, Lee R, Scheinman MM. Electrophysiological response of the right atrium to ibutilide during typical atrial flutter. Circulation 2002;106:814-9.
8. Guo GH, Ellenbogen KA, Wood MA, Stambler BS. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. J Am Coll Cardiol 1996;27:1083-9.
9. Singh BN. Acute conversion of atrial fibrillation and flutter: direct current cardioversion versus intravenously administered pure class III agents. J Am Coll Cardiol 1997;29:391-3.
10. Cosio FG, Delpon E. New antiarrhythmic drugs for atrial flutter and atrial fibrillation. Circulation 2002;105: 276-8.
11. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991;84:1831-51.
12. Tai C-T, Chen S-A. Mechanisms of antiarrhythmic drug action on termination of atrial flutter. Pacing Clin Electrophysiol 2001;24:824-34.
13. Wellens HJJ. Contemporary management of atrial flutter. Circulation 2002;106:649-52.
14. Crijns HJ, Van Gelder IC, Kingma JH, Dunselman PH, Gosselink AT, Lie KI. Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug. Eur Heart J 1994;15:1403-8.
15. Tai CT, Chen SA, Feng AN, Yu WC, Chen YJ, Chang MS. Electrophysiologic effects of class I and class II antiarrhythmia drugs on typical atrial flutter: insights into the mechanism of termination. Circulation 1998;97: 1935-45.
16. Vos MA, Golitsyn SR, Stangl K, Ruda MY, Van Wijk LV, Harry JD et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart 1998;79:568-5.
17. Podrid PJ. Amiodarone: reevaluation of an old drug. Ann Intern Med 1995;122:689-700.
18. Yang T, Snyders DJ, Roden DM. Ibutilide, a methane-sulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+current (IKr) in AT-1 cells: concentration-, time-, voltage-, and use-dependent effects. Circulation 1995;91:1799-806.
19. Lee KS. Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na+current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992;262:99-108.
20. Murray KT. Ibutilide. Circulation 1998;97:493-7.
21. Volgman AS, Carberry PA, Stambler B, Lewis WR, Dunn GH, Perry KT et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998;31:1414-9.
22. VanderLugt JT, Mattioni T, Denker S, Torchiana D, Ahern T, Wakefield LK et al. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation 1999;100:369-75.
23. Abi-Mansour P, Carberry PA, McCowan RJ, Henthorn RW, Dunn GH, Perry KT. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators. Am Heart J 1998;136:632-42.
24. Varriale P, Sedighi A. Acute management of atrial fibrillation and atrial flutter in the critical care unit: should it be ibutilide? Clin Cardiol 2000;23:265-8.
25. Eversole A, Hancock W, Johns T, Lopez LM, Conti CR. Ibutilide: efficacy and safety in atrial fibrillation and atrial flutter in a general cardiology practice. Clin Cardiol 2001;24:521-5.
26. Stambler BS, Wood MA, Ellenbogen KA. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am J Cardiol 1996;77:960-6.
27. Oral H, Souza JJ, Michaud GF, Knight BP, Goyal R, Strickberger SA et al. Facilitating transthoracic cardio-version of atrial fibrillation with ibutilide pre-treatment. N Engl J Med 1999;340:1849-54.
28. Roden DM. Ibutilide and the treatment of atrial arrhythmias: a new drug - almost unheralded - is now available to US physicians. Circulation 1996;94:1499-502.
29. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc Res 1993;27:2186-93.
30. Taylor CT, Donaldson AR. Safety and effectiveness of ibutilide in a community hospital. Pharmacotherapy 2001;21:488-92.